Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer—a pilot study
Open Access
- 15 February 2005
- journal article
- clinical trial
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 8 (1) , 91-94
- https://doi.org/10.1038/sj.pcan.4500784
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Prostate carcinoma presentation, diagnosis, and stagingCancer, 2003
- An evaluation of bicalutamide in the treatment of prostate cancerExpert Opinion on Pharmacotherapy, 2002
- Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trialUrology, 1997
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancerUrology, 1995
- Casodex–-mechanisms of action and opportunities for usageCancer, 1993
- Cyproterone acetate–-mechanism of action and clinical effectiveness in prostate cancer treatmentCancer, 1993
- Is disease flare a problem?Cancer, 1993
- Zoladex and Flutamide Versus Bilateral OrchiectomyCancer, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone AgonistJournal of Urology, 1987